Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

UCB's CIMZIA(R) (certolizumab Pegol) Approved By The U.S. FDA For Adult Patients Suffering From Moderate To Severe Rheumatoid Arthritis
UCB announced that the U.S. Food and Drug Administration (FDA) approved Cimzia®, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). Cimzia® can be dosed at 400 mg initially and at weeks two and four, followed by 200 mg every other week; for maintenance dosing, 400 mg every four weeks can be considered.

U.S. Health and Human Services Secretary Sebelius Releases New Report On Health Disparities
U.S. Health and Human Services (HHS) Secretary Kathleen Sebelius today released a new report on health disparities in America and participated in a White House Health Care Stakeholder Discussion on the importance of reform that reduces disparities that exist in our current health care system. The new report Health Disparities: A Case for Closing the Gap is available at http://www.HealthReform.gov.
News of the day
Three Hospitals Honored For Commitment To Quality
Three U.S. hospitals were recognized today for their leadership and innovation in quality, safety and commitment to patient care. The 2009 American Hospital Association-McKesson Quest for Quality Prize® was awarded to Bronson Methodist Hospital in Kalamazoo, Mich., which will receive $75,000. Bronson Methodist Hospital, a 380-bed hospital serving patients and communities in southwest Michigan and northern Indiana, was selected by a multi-disciplinary committee of health care quality and patient safety experts based on its culture of quality and efforts to achieve the Institute of Medicine"s six quality aims for health care. Beth Israel Deaconess Medical Center in Boston was honored as the finalist and will receive $12,500. Duke University Hospital in Durham, N.C., received the Citation of Merit.
Health Insurance

AbbeyMoor Medical Receives FDA Approval For Design Improvements To The Spanner(TM) Prostatic Stent

AbbeyMoor Medical Inc., a developer and manufacturer of medical devices for the management and treatment of prostatic obstruction, announced that it has received PMA approval from the US Food and Drug Administration (FDA) for design changes to their flagship product, The Spanner(TM) Prostatic Stent. "These changes are aimed at further improving patient comfort over the current highly accepted levels," said Darren Cook, director of marketing with the company. "Our goal is to hear an even greater percentage of our patient"s state that they are not aware of the device"s presence." According to Mark Whalen, VP of product development with the company, "The approved changes to the device result in a significant increase in flexibility over the current Spanner design with no impact to the ease of delivery and removal of the device." The Spanner is a temporary prostatic stent designed to aid men who are experiencing difficulty in urination due to prostatic obstruction. Device placement can be performed in a physician office and does not require cystoscopy or anesthesia for placement. The Spanner is an alternative to indwelling catheterization, intermittent catheterization, or the use of a suprapubic tube in some patients. About AbbeyMoor Medical AbbeyMoor Medical is a privately held company that develops innovative medical devices focused on the management and treatment of male voiding dysfunction. The company"s initial focus is on the development and commercialization of The Spanner. AbbeyMoor Medical, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009